INVAP, Argentina's state-owned technology company based in Bariloche, is one of the world's premier designers and builders of research and radioisotope production reactors. Its portfolio includes Australia's OPAL reactor (20 MW, commissioned 2007), Egypt's ETRR-2 (22 MW, commissioned 1997), Algeria's NUR reactor, and multiple other facilities. These research reactors produce medical radioisotopes (Mo-99 for nuclear medicine), neutron beams for materials science, and silicon doping for semiconductor applications.
The technology encompasses reactor physics design, safety analysis, control system engineering, neutron reflector optimization, and low-enriched uranium (LEU) fuel assembly design. INVAP's competitive advantage is offering turnkey research reactor packages — from feasibility study through construction, commissioning, and operator training — at costs significantly below major nuclear nations' offerings. The company's ability to work with LEU fuels (avoiding weapons-grade HEU) aligns with non-proliferation goals.
This export capability is remarkable for a developing nation: INVAP competes against French, Russian, Chinese, and South Korean nuclear companies in international tenders. The Australian OPAL contract — won in open competition against European and Asian bidders — demonstrated that Argentine nuclear engineering matches the quality of established nuclear powers. As global demand for medical isotopes (particularly Mo-99/Tc-99m for 40 million diagnostic procedures annually) drives new research reactor construction, INVAP's order pipeline remains robust.